Please assess the completion status of the following clinical trial:

Trial Title: Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12 to 17.~* Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.~* History of AD for ≥1 year.~* History of topical corticosteroid (TCS; Europe: Class 3 or higher; US: Class 4 or lower) and/or topical calcineurin inhibitor (TCI) treatment failure or subjects for whom these topical AD treatments are medically inadvisable.~* AD involvement of ≥10% body surface area at screening and baseline.~* Stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation.~Exclusion Criteria:~* Active dermatologic conditions that may confound the diagnosis of AD.~* Use of tanning beds or phototherapy within 6 weeks prior to randomisation.~* Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to randomisation.~* Treatment with TCS, TCI, or topical phosphodiesterase 4 (PDE-4) inhibitor within 2 weeks prior to randomisation.~* Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin E) including dupilumab or investigational biologic agents.~* Active skin infection within 1 week prior to randomisation.~* Clinically significant infection within 4 weeks prior to randomisation.~* A helminth parasitic infection within 6 months prior to the date informed consent is obtained.~* Tuberculosis requiring treatment within the 12 months prior to screening.~* Known primary immunodeficiency disorder.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen A.
- Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen B.
- Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen A.
- Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen B.
- Placebo initial-> Placebo maintenance (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52 (maintenance period):~Placebo continuation SC injection regimen A.
- Tralokinumab (Dose1) initial-> Open-label tralokinumab (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids
- Tralokinumab (Dose2) initial-> Open-label tralokinumab (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids
- Placebo initial-> Open-label tralokinumab (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete